A Study of Paliperidone Palmitate 6-Month Formulation
Status:
Completed
Trial end date:
2020-05-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that injection cycles consisting of a single
administration of paliperidone palmitate 6-month (PP6M) are not less effective than 2
sequentially administered injections of paliperidone palmitate 3-month PP3M) (350 or 525 mg
eq.) for the prevention of relapse in participants with schizophrenia previously stabilized
on corresponding doses of paliperidone palmitate 1-month (PP1M) (100 or 150 mg eq.) or PP3M
(350 or 525 mg eq.).